DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Firms / Samsara Biocapital, LLC
Samsara Biocapital, LLC
Founder’s Corner Investing to create transformative therapeutics for patients. The Tree of Life Darwin’s Tree of Life (1837) Darwin’s Origin of Species is the foundation of evolutionary biology, and is unquestionably one of the most important and influential texts in all of science. His thoughts on natural selection and how new species can branch out […]
venture manager, reported GAV $1,744M across 3 vehicles
Importance
47
elevated
Active deployment
40
elevated
Emerging
0
low
Completeness
69
high
Freshness
100
high
Research priority
17
moderate
Identity and regulatory footprint
- Headquarters
- unknown
- Office address
- unknown
- Business phone
- 650-285-4270adviserinfo.sec.gov
- Website
- HTTP://WWW.SAMSARACAP.COM/
- SEC adviser type
- registered investment adviseradviserinfo.sec.gov
- SEC exemption claimed
- unknown
- Latest Form ADV
- Jun 26, 2026
- Private funds reported
- 3 (3 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $2.3Badviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- Regulatory AUM
- $2.2Bthe adviser's RAUM, a regulatory measure, never a fund size
- Employees
- 31
- business email
- info@samsaracap.comsamsaracap.compublished by the subject
- business phone
- 650-285-4270adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
4 observed deals
Stated (the firm’s website)
- Sectors
- biotech
- Stages
- not stated or not yet read
- Geography
- not stated
- Check size
- not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation
series a 50%series b 50%
Stage at first entry
series a 50%series b 50%
Sectors
unknown 50%Biotechnology 50%
lead rate 0%follow-on rate 0%new logos, 12 months 4
Funds and vehicles
3 reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| Smsr B1, L.P. | Fund | 2023 adv first reported | Active deployment | $121M Mar 31, 2024 | 1 | unknown | unknown |
| 565 Spv I, L.P. | SPV or co-invest vehicle | 2020 adv first reported | Mature | $11,295 Mar 31, 2024 | 8 | unknown | unknown |
| SMM Spv I, LLC | SPV or co-invest vehicle | 2016 form d first sale | Harvest | $1.6B Mar 31, 2024 | 154 | $7.0M of $7.0M | Mar 1, 2017 |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
39 current, 2 departed
Dolca Thomas
Board or advisorySenior Advisor
Reena Jashnani-Slusarz
Board or advisorySenior Advisor
Srini’s Take
Founder or executiveFounder’s Corner
Kelly Tomera
Investor relationsVice President of Investor Relations & Marketing
Liz Grace
Investor relationsHead of Investor Relations & Marketing
Srini Akkaraju
Managing partnerFounder & Managing Partner
Indrani Rebbapragada
OtherSr. Dir Project & Portfolio Management
Abe Bassan
PartnerPartner
Michael P. Dybbs
PartnerPartner · since Feb 1, 2017
Mike Dybbs
PartnerPartner
Srinivas Akkaraju
PartnerManager Of Samsara Biocapital, Llc · since Sep 1, 2016
Abrar Hussain
Platform and operationsGeneral Counsel And Chief Compliance Officer · since Jan 1, 2023
Andrew Walker
Platform and operationsAssistant Controller
Carolyn Nguyen
Platform and operationsDeputy General Counsel
Marie Chang
Platform and operationsAssociate Director, Finance
Meysis Lam
Platform and operationsAccounting Supervisor – Portfolio
Miran Nasruddin Ahmad
Platform and operationsChief Financial Officer · since Jan 1, 2023
Noushin Vaccani
Platform and operationsExec Assistant/Operations Manager
Riki Harada
Platform and operationsVice President of Finance
Matt Eckler
PrincipalPrincipal, Public Investing
Mitchell Mutz
PrincipalSenior Principal
Alan Eisenberg
Venture partnerVenture Partner
Betsy Santos
Venture partnerVenture Partner, Chief People Officer
Dan Spiegelman
Venture partnerVenture Partner
David Parry
Venture partnerVenture Partner
Eric Dobmeier
Venture partnerVenture Partner
Guna Rajagopal
Venture partnerVenture Partner
Jim P. Edwards
Venture partnerVenture Partner
John Orwin
Venture partnerVenture Partner
Keith Gottesdiener
Venture partnerVenture Partner
Marcos Milla
Venture partnerVenture Partner
Ravi Rao
Venture partnerVenture Partner
Robert Baffi
Venture partnerVenture Partner
Robert Stein
Venture partnerVenture Partner
Stephen Shuttleworth
Venture partnerVenture Partner
Thomas F. Bumol
Venture partnerVenture Partner
Clara Dong
Vice presidentSenior Associate
Ehi Akhirome
Vice presidentSenior Associate
Jake Bieber-Dishart
Vice presidentSenior Associate
2 departed (kept with end dates)
- Richard D. van Doren · Cfo And Cco · Feb 1, 2017 to Mar 31, 2023 Inference
- Eric Dobmeier · Venture Partner · ? to Sep 16, 2026 Inference
Investments on record
4 edges, 4 companies, 1 partner-attributed
| Company | Round | Role | Partner | Round size | This investor | Date | Source |
|---|---|---|---|---|---|---|---|
| Investor Portal | portfolio listing | unknown | unknown | unknown | unknown | Sep 12, 2026 | Fact Venture organization websites (about, team, portfolio, thesis, news pages) |
| Coultreon Biopharma | Series A · Series A | participant | unknown | $125M | unknown | Apr 28, 2026 | Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) |
| Bonum Therapeutics, Inc. | board seat | unknown · board | Mitchell Mutz (strongly supported) | unknown | unknown | Apr 17, 2026 | Inference SEC EDGAR Form D data sets (quarterly) |
| Ambrosia Biosciences Inc. | Series B · Series B | participant | unknown | $100M | unknown | Mar 31, 2026 | Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) |
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
38 relationships from shared deals, counted for the whole firm
Sofinnova Investments, Inc. 2 shared · recurring · they led 1Orei Advisors LP 1 shared · one timeTritium Partners 1 shared · one timeGrandBanks Capital 1 shared · one timeUncommon Denominator Management LLC 1 shared · one timeDFJ Growth 1 shared · one timeHivemind Capital Partners LLC 1 shared · one timeGreenridge Growth Partners 1 shared · one timeCresta Fund Management LLC 1 shared · one timeFTV Capital 1 shared · one timeArctaris Impact Investors 1 shared · one time5th Century Partners 1 shared · one timeKamerra Holdings, LLC 1 shared · one timeNSV Management LLC 1 shared · one timeHakluyt Capital Limited 1 shared · one timeRally Ventures Management, LLC 1 shared · one timeNCN 1 shared · one timeUnless Management LP 1 shared · one timePlural Uk Management 1 shared · one time4x4 Capital 1 shared · one timeDN Capital (US), Inc 1 shared · one timeMcwhorter Ventures, LLC 1 shared · one timeCarnelian Energy Capital Management, LP 1 shared · one timeRice Park Capital 1 shared · one timeBlueprint Local LLC 1 shared · one timeFGC Management Co., LLC 1 shared · one timeLAS Olas Venture Capital 1 shared · one timeGalapagos 1 shared · one timeBalyasny Asset Management L.P. 1 shared · one timeRegeneron Ventures 1 shared · one timeLongwood Fund 1 shared · one timeFinchley Healthcare Ventures 1 shared · one timeLuma Group 1 shared · one timeDeep Track Capital 1 shared · one timeBVF Partners 1 shared · one timeBlue Owl Healthcare Opportunities 1 shared · one timeRedmile Group 1 shared · one timeBoulder Ventures 1 shared · one time
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
11 dated events
- Sep 16, 2026Eric Dobmeier (Venture Partner) no longer on the team page of Samsara Biocapital, LLCPerson leftPeopleInferenceEric DobmeierVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 15, 2026Samsara Biocapital, LLC: SEED_FUND_MANAGER -> INSTITUTIONAL_VC (venture manager, reported GAV $1,744M across 3 vehicles)Classification changedClassificationInferenceno URL
- Mar 31, 2023Richard D. van Doren (Cfo And Cco) no longer on Schedule A of Samsara Biocapital, LLC
- Mar 31, 2023Smsr B1, L.P. first reported on Form ADV by Samsara Biocapital, LLC (Venture Capital Fund), GAV $80,449,524Fund first reported on Form ADVFundsFactSmsr B1, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Jan 1, 2023Miran Nasruddin Ahmad joined Schedule A of Samsara Biocapital, LLC as Chief Financial Officer
- Jan 1, 2023Abrar Hussain joined Schedule A of Samsara Biocapital, LLC as General Counsel And Chief Compliance Officer
- Mar 30, 2020565 Spv I, L.P. first reported on Form ADV by Samsara Biocapital, LLC (Venture Capital Fund), GAV $8,258,932Fund first reported on Form ADVFundsFact565 Spv I, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 20, 2017Samsara Biocapital, LLC first filed Form ADV (ERA)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 20, 2017SMM Spv I, LLC first reported on Form ADV by Samsara Biocapital, LLC (Venture Capital Fund), GAV $11,771,437Fund first reported on Form ADVFundsFactSMM Spv I, LLCSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Feb 1, 2017Michael P. Dybbs joined Schedule A of Samsara Biocapital, LLC as Partner
- Feb 1, 2017Richard D. van Doren joined Schedule A of Samsara Biocapital, LLC as Cfo And Cco
Classification history
- Sep 15, 2026Institutional venture firm (probable, 80%, cls-1)venture manager, reported GAV $1,744M across 3 vehicles
- Sep 12, 2026Seed fund manager (probable, 80%, cls-1)seed vehicles only
Evidence
47 observations from 3 sources